Skip to main content

GENARRAYTION, INC. ANNOUNCES MULTIFLEX™ MOLECULAR ASSAY OPTIMIZATION FOR THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL AND BIOLOGICAL DEFENSE (JPEO CBD) IN SUPPORT OF THE GLOBAL BIOSURVEILLANCE TECHNOLOGY INITIATIVE (GBTI)

By November 9, 2015News
genarraytion-logo

genarraytion-logo

GenArraytion, Inc., is pleased to announce the successful completion of a project for the optimization of five separate MultiFLEX™ molecular assay panels for the identification of over 65 infectious disease targets of world-wide US military concern.  The project was in support of the Joint Program Executive Office for Chemical and Biological Defense’s (JPEO CBD) Global Biosurveillance Technology Initiative (GBTI), which is working to improve the biosurveillance capacity for the Department of Defense to systematically deploy an infectious disease testing capability to improve detection capacity while connecting these labs to a networked analytics and communication hub, JPEO provides worldwide users with timely, actionable, and operationally valuable information enabling a more effective response to a health crisis anywhere in the world.  The MultiFLEX molecular assays are infectious disease panels with 12 to 20 individual molecular targets for fever causing and vector born microorganisms of military concern across the globe. The tests are designed to work on the Luminex MagPix instruments which have been distributed to the military area labs around the world.

{iframe}http://www.genarraytion.com/nov-9-genarraytion-press-release{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.